Showing results (1-10 of 599) with videos related to
Sort By:
Pageof 60
Statistics in Biopharmaceutical Research|March 25, 2014
Statistical approaches to analyzing HIV-1 neutralizing antibody assay dataXuesong Yu, Peter B Gilbert, Catarina E Hioe, et al.Journal of Virology|June 14, 2019
Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine TrialSusan Zolla-Pazner, Peter B GilbertVaccine|January 11, 2011
Quantitative assessment of masking of neutralization epitopes in HIV-1Alpna Agarwal, Catarina E Hioe, James Swetnam, et al.Plos Pathogens|January 26, 2018
Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutationsChitra Upadhyay, Roya Feyznezhad, Weiming Yang, et al.Plos One|April 28, 2010
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesCatarina E Hioe, Terri Wrin, Michael S Seaman, et al.Journal of the American Society for Mass Spectrometry|August 1, 2006
The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometryJason G Williams, Kenneth B Tomer, Catarina E Hioe, et al.Plos One|October 23, 2015
Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal AntibodiesGuomiao Shen, Chitra Upadhyay, Jing Zhang, et al.The Journal of Infectious Diseases|July 23, 2002
High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progressionPeter C Chien, Sandra Cohen, Cynthia Kleeberger, et al.Science (New York, N.Y.)|July 12, 2014
A critical question for HIV vaccine development: which antibodies to induce?Susan Zolla-PaznerHuman Antibodies|May 25, 2006
Improving on nature: focusing the immune response on the V3 loopSusan Zolla-PaznerPageof 60